<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0212-1611</journal-id>
<journal-title><![CDATA[Nutrición Hospitalaria]]></journal-title>
<abbrev-journal-title><![CDATA[Nutr. Hosp.]]></abbrev-journal-title>
<issn>0212-1611</issn>
<publisher>
<publisher-name><![CDATA[Grupo Arán]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0212-16112024000900015</article-id>
<article-id pub-id-type="doi">10.20960/nh.05275</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Relationship between serum omentin-1 levels and nascent metabolic syndrome in Caucasian patients with obesity]]></article-title>
<article-title xml:lang="es"><![CDATA[Relación entre los niveles séricos de omentina-1 y el síndrome metabólico incipiente en pacientes caucásicos con obesidad]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[de Luis]]></surname>
<given-names><![CDATA[Daniel A]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Izaola]]></surname>
<given-names><![CDATA[Olatz]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Primo]]></surname>
<given-names><![CDATA[David]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Valladolid Hospital Clínico Universitario Servicio de Endocrinología y Nutrición]]></institution>
<addr-line><![CDATA[Valladolid ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2024</year>
</pub-date>
<volume>41</volume>
<numero>6</numero>
<fpage>1231</fpage>
<lpage>1237</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S0212-16112024000900015&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S0212-16112024000900015&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S0212-16112024000900015&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background and aims: omentin-1 might present a potential role in metabolic syndrome (MS). The aim of our investigation was to evaluate the relationship between omentin-1 and nascent MS.  Methods: we carried out a cross-sectional study in 606 obese subjects. Adiposity parameters, blood pressure, fasting blood glucose, insulin levels, insulin resistance (HOMA-IR), triglyceride and glucose index (TyG), lipid profile, C-reactive protein, omentin-1, and prevalence of nascent MS were determined.  Results: 307 subjects had MS (49.2 %) and 299 did not show MS (50.8 %). Subjects without MS have higher omentin-1 levels (delta: 78.0 ± 13.8 ng/ml; p = 0.01). A negative correlation was observed between omentin-1 and adiposity parameters, glucose, insulin, HOMA-IR, TyG index and triglycerides in both groups. And a positive correlation was observed with HDL-cholesterol. BMI (OR = 1.17, 95 % CI = 1.09-1.31; p = 0.02), HOMA-IR (OR = 5.21, 95 % CI = 1.69-21.11; p = 0.01) and omentin-1 (OR = 0.95, 95 % CI = 0.94-0.97; p = 0.02) remained in the final model as predictors of MS. The cut-off point according to the Youden index was 372.45 ng/ml of omentin-1, to predict MS.  Conclusions: Caucasian patients with obesity had clearly lower serum omentin-1 levels in the presence of nascent MS. An inverse correlation was demonstrated with adiposity parameters, insulin resistance and triglycerides. And a direct correlation with HDL-cholesterol was reported.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Antecedentes y objetivos: la omentina-1 podría tener un papel potencial en el síndrome metabólico (SM). El objetivo de nuestra investigación fue evaluar la relación entre la omentina-1 y el SM incipiente.  Métodos: realizamos un estudio transversal en 606 sujetos obesos. Se determinaron los parámetros de adiposidad, la presión arterial, la glucemia en ayunas, los niveles de insulina, la resistencia a la insulina (HOMA-IR), el índice de triglicéridos y glucosa (ITyG), el perfil lipídico, la proteína C-reactiva, la omentina-1 y la prevalencia del SM incipiente.  Resultados: 307 sujetos tenían SM (49,2 %) y 299 no presentaban SM (50,8 %). Los sujetos sin SM tienen niveles más altos de omentina-1 (delta: 78,0 ± 13,8 ng/ml; p = 0,01). Se observó una correlación negativa entre la omentina-1 y los parámetros de adiposidad, la glucosa, la insulina, el HOMA-IR, el índice TyG y los triglicéridos en ambos grupos. Se observó una correlación positiva con el colesterol HDL. EL IMC (OR = 1,17, IC 95 % = 1,09-1,31; p = 0,02), el HOMA-IR (OR = 5,21, IC 95 % = 1,69-21,11; p = 0,01) y la omentina-1 (OR = 0,95, IC 95 % = 0,94-0,97; p = 0,02) permanecieron en el modelo final como predictores del SM. El punto de corte según el índice de Youden fue 372,45 ng/ml de omentina-1 para predecir el SM.  Conclusiones: los pacientes caucásicos con obesidad tenían niveles séricos de omentina-1 claramente más bajos en presencia de SM incipiente. Se demostró una correlación inversa con los parámetros de adiposidad, resistencia a la insulina y triglicéridos. Y se detectó una correlación directa con el colesterol HDL.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Insulin resistance]]></kwd>
<kwd lng="en"><![CDATA[Nascent metabolic syndrome]]></kwd>
<kwd lng="en"><![CDATA[Obesity]]></kwd>
<kwd lng="en"><![CDATA[Omentin-1]]></kwd>
<kwd lng="es"><![CDATA[Resistencia a la insulina]]></kwd>
<kwd lng="es"><![CDATA[Síndrome metabólico naciente]]></kwd>
<kwd lng="es"><![CDATA[Obesidad]]></kwd>
<kwd lng="es"><![CDATA[Omentina-1]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fleming]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Thomson]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Graetz]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Margono]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global, regional, and national prevalence of overweight and obesity in children and adults during 1980&#8211;2013: a systematic analysis for the global burden of disease study 2013]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2014</year>
<volume>384</volume>
<page-range>766-81</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hamdy]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The role of adipose tissue as an endocrine gland]]></article-title>
<source><![CDATA[Curr Diab Rep]]></source>
<year>2005</year>
<volume>5</volume>
<page-range>317-9</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Maury]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Brichard]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome]]></article-title>
<source><![CDATA[Mol Cell Endocrinol]]></source>
<year>2010</year>
<volume>314</volume>
<page-range>1-16</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[RZ]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Pray]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[HB]]></given-names>
</name>
<name>
<surname><![CDATA[Hansen]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of omentin as a novel depotspecific adipokine in human adipose tissue: possible role in modulating insulin action]]></article-title>
<source><![CDATA[Am J Physiol Endocrinol Metab]]></source>
<year>2006</year>
<volume>290</volume>
<page-range>1253-61</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[BK]]></given-names>
</name>
<name>
<surname><![CDATA[Adya]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Randeva]]></surname>
<given-names><![CDATA[HS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omentin: a novel link between inflammation, diabesity, and cardiovascular disease]]></article-title>
<source><![CDATA[Trends Cardiovasc Med]]></source>
<year>2010</year>
<volume>20</volume>
<page-range>143-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ouchi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Lugus]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Walsh]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adipokines in inflammation and metabolic disease]]></article-title>
<source><![CDATA[Nat Rev Immunol]]></source>
<year>2011</year>
<volume>11</volume>
<page-range>85-97</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<collab>Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III)</collab>
<article-title xml:lang=""><![CDATA[Executive summary of the Third Report of the National Cholesterol Education Program (NCEP)]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2001</year>
<volume>285</volume>
<page-range>2486-97</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Luis]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Izaola]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Primo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Aller]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relation of a variant in adiponectin gene (rs266729) with metabolic syndrome and diabetes mellitus type 2 in adult obese subjects]]></article-title>
<source><![CDATA[Eur Rev Med Pharmacol Sci]]></source>
<year>2020</year>
<volume>24</volume>
<page-range>10646-52</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cornier]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Dabelea]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[Lindstrom]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Steig]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Stob]]></surname>
<given-names><![CDATA[NR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The metabolic syndrome]]></article-title>
<source><![CDATA[Endocr Rev]]></source>
<year>2008</year>
<volume>29</volume>
<page-range>777-822</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bremer]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Devaraj]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Afify]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Jialal]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adipose tissue dysregulation in patients with metabolic syndrome]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2011</year>
<volume>96</volume>
<page-range>1782-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bremer]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Jialal]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adipose tissue dysfunction in nascent metabolic syndrome]]></article-title>
<source><![CDATA[J Obes]]></source>
<year>2013</year>
<volume>2013</volume>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jialal]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Devaraj]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Adams-Huet]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Kaur]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Increased cellular and circulating biomarkers of oxidative stress in nascent metabolic syndrome]]></article-title>
<source><![CDATA[J Clin Endocrinol Metab]]></source>
<year>2012</year>
<volume>97</volume>
<page-range>1844-50</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vu]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sidhom]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Bredbeck]]></surname>
<given-names><![CDATA[BC]]></given-names>
</name>
<name>
<surname><![CDATA[Kosmiski]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Aquilante]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of the relationship between circulating omentin-1 concentrations and components of the metabolic syndrome in adults without type 2 diabetes or cardiovascular disease]]></article-title>
<source><![CDATA[Diabetol Metab Syndr]]></source>
<year>2014</year>
<volume>6</volume>
<page-range>4-10</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lukaski]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[PE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Assessment of fat-free mass using bioelectrical impedance measurements of the human body]]></article-title>
<source><![CDATA[Am J Clin Nutr]]></source>
<year>1985</year>
<volume>41</volume>
<page-range>810-7</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Friedewald]]></surname>
<given-names><![CDATA[WT]]></given-names>
</name>
<name>
<surname><![CDATA[Levy]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Fredrickson]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge]]></article-title>
<source><![CDATA[Clin Chem]]></source>
<year>1972</year>
<volume>18</volume>
<page-range>499-502</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mathews]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
<name>
<surname><![CDATA[Hosker]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Rudenski]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Naylor]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Treacher]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Homeostasis model assessment: insulin resistance and beta cell function from fasting plasma glucose and insulin concentrations in man]]></article-title>
<source><![CDATA[Diabetologia]]></source>
<year>1985</year>
<volume>28</volume>
<page-range>412-4</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Primo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Izaola]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[de Luis]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Triglyceride-Glucose Index Cutoff Point Is an Accurate Marker for Predicting the Prevalence of Metabolic Syndrome in Obese Caucasian Subjects]]></article-title>
<source><![CDATA[Ann Nutr Metab]]></source>
<year>2023</year>
<volume>79</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>70-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cetin Sanlialp]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Nar]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Nar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relationship between circulating serum omentin-1 levels and nascent metabolic syndrome in patients with hypertension]]></article-title>
<source><![CDATA[J Investig Med]]></source>
<year>2022</year>
<volume>70</volume>
<page-range>780-5</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buyukinan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Atar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Can]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Pirgon]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Guzelant]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Deniz]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The association between serum vaspin and Omentin-1 levels in obese children with metabolic syndrome]]></article-title>
<source><![CDATA[Metab Syndr Relat Disord]]></source>
<year>2018</year>
<volume>16</volume>
<page-range>76-81</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kilic]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Oguz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Uzunlulu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Plasma omentin-1 levels are similar in nondiabetic metabolic syndrome patients and healthy subjects]]></article-title>
<source><![CDATA[J Endocrinol Metab]]></source>
<year>2011</year>
<volume>1</volume>
<page-range>182-7</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Changes of serum omentin-1 levels in normal subjects, type 2 diabetes and type 2 diabetes with overweight and obesity in Chinese adults]]></article-title>
<source><![CDATA[Ann Endocrinol]]></source>
<year>2014</year>
<volume>75</volume>
<page-range>171-5</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Luis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Izaola]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Primo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Aller]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Randomized Trial with Two Hypocaloric Diets with Different Lipid Profiles and Effects on Serum Omentin-1 Levels in Obese Subjects]]></article-title>
<source><![CDATA[Dis Markers]]></source>
<year>2022</year>
<volume>2022</volume>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hossein-Nezhad]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mirzaei]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Alatab]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Circulating Omentin-1 in obesity and metabolic syndrome status compared to control subjects]]></article-title>
<source><![CDATA[Endocrinol Metabol Syndrome]]></source>
<year>2012</year>
<volume>S1</volume>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[de Souza Batista]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[R-Z]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[M-J]]></given-names>
</name>
<name>
<surname><![CDATA[Glynn]]></surname>
<given-names><![CDATA[NM]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[DZ]]></given-names>
</name>
<name>
<surname><![CDATA[Pray]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Omentin plasma levels and gene expression are decreased in obesity]]></article-title>
<source><![CDATA[Diabetes]]></source>
<year>2007</year>
<volume>56</volume>
<page-range>1655-61</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greulich]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Maxhera]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Rijzewijk]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[van der Meer]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Jonker]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardioprotective properties of omentin-1 in type 2 diabetes: evidence from clinical and in vitro studies]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2013</year>
<volume>8</volume>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Long]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ren]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Pang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Changes of serum omentin levels and relationship between omentin and adiponectin concentrations in type 2 diabetes mellitus]]></article-title>
<source><![CDATA[Exp Clin Endocrinol Diabetes]]></source>
<year>2011</year>
<volume>119</volume>
<page-range>257-63</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shang]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[XT]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[QS]]></given-names>
</name>
<name>
<surname><![CDATA[Xue]]></surname>
<given-names><![CDATA[YS]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serum omentin-1 levels are inversely associated with the presence and severity of coronary artery disease in patients with metabolic syndrome]]></article-title>
<source><![CDATA[Biomarkers]]></source>
<year>2011</year>
<volume>16</volume>
<page-range>657-62</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Xue]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relationships between serum omentin-1 concentration, body composition and physical activity levels in older women]]></article-title>
<source><![CDATA[Medicine (Baltimore)]]></source>
<year>2021</year>
<volume>12</volume>
<numero>100</numero>
<issue>100</issue>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alizadeh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Mirzaei]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Mohammadi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Keshavarz]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Maghbooli]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Circulating omentin-1 might be associated with metabolic health status in different phenotypes of body size]]></article-title>
<source><![CDATA[Arch Endocrinol Metab]]></source>
<year>2017</year>
<volume>61</volume>
<page-range>567-74</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
